You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

~ Buy the PEMAZYRE (pemigatinib) Drug Profile, 2024 PDF Report in the Report Store ~

PEMAZYRE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Pemazyre, and when can generic versions of Pemazyre launch?

Pemazyre is a drug marketed by Incyte Corp and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-five patent family members in thirty-eight countries.

The generic ingredient in PEMAZYRE is pemigatinib. One supplier is listed for this compound. Additional details are available on the pemigatinib profile page.

DrugPatentWatch® Generic Entry Outlook for Pemazyre

Pemazyre was eligible for patent challenges on April 17, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 30, 2035. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Ask!
Questions you can ask:
  • What is the 5 year forecast for PEMAZYRE?
  • What are the global sales for PEMAZYRE?
  • What is Average Wholesale Price for PEMAZYRE?
Summary for PEMAZYRE
International Patents:135
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 36
Clinical Trials: 7
Patent Applications: 58
Drug Prices: Drug price information for PEMAZYRE
What excipients (inactive ingredients) are in PEMAZYRE?PEMAZYRE excipients list
DailyMed Link:PEMAZYRE at DailyMed
Drug patent expirations by year for PEMAZYRE
Drug Prices for PEMAZYRE

See drug prices for PEMAZYRE

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PEMAZYRE
Generic Entry Date for PEMAZYRE*:
⤷  Sign Up
Constraining patent/regulatory exclusivity:
⤷  Sign Up
NDA:
213736
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PEMAZYRE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestPhase 2
Incyte Biosciences International SàrlPhase 2
Tianjin Medical University Cancer Institute and HospitalPhase 2

See all PEMAZYRE clinical trials

Pharmacology for PEMAZYRE
Drug ClassKinase Inhibitor
Mechanism of ActionKinase Inhibitors
Multidrug and Toxin Extrusion Transporter 1 Inhibitors
Organic Cation Transporter 2 Inhibitors
P-Glycoprotein Inhibitors
Paragraph IV (Patent) Challenges for PEMAZYRE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PEMAZYRE Tablets pemigatinib 4.5 mg, 9 mg and 13.5 mg 213736 1 2024-04-17

US Patents and Regulatory Information for PEMAZYRE

PEMAZYRE is protected by nine US patents and four FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of PEMAZYRE is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting PEMAZYRE

Substituted tricyclic compounds as FGFR inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING ONCE DAILY A TABLET CONTAINING ABOUT 0.5 MG TO ABOUT 10 MG OF PEMIGATINIB


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB QD FOR 14 DAYS THEN NOT ADMINISTERING PEMIGATINIB FOR 7 DAYS IN A 21-DAY CYCLE


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB IN A DAILY DOSE OF ABOUT 5 MG TO ABOUT 20 MG


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS

Substituted tricyclic compounds as FGFR inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting PEMAZYRE

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

INDICATED FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
Exclusivity Expiration: ⤷  Sign Up

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-003 Apr 17, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-001 Apr 17, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-002 Apr 17, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-002 Apr 17, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-003 Apr 17, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-003 Apr 17, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-001 Apr 17, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Sign Up

EU/EMA Drug Approvals for PEMAZYRE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Incyte Biosciences Distribution B.V. Pemazyre pemigatinib EMEA/H/C/005266
Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.		 Authorised no no yes 2021-03-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Subscribe to access the full database, or Sign Up

International Patents for PEMAZYRE

When does loss-of-exclusivity occur for PEMAZYRE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1424
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DE RECEPTORES DEL FACTOR DE CRECIMIENTO DEL FIBROPLASTO (FGFR)
Estimated Expiration: ⤷  Sign Up

Patent: 7823
Patent: COMPUESTOS TRICÍCLICOS SUSTITUIDOS COMO INHIBIDORES DE RECEPTORES DEL FACTOR DE CRECIMIENTO DEL FIBROBLASTO (FGFR)
Estimated Expiration: ⤷  Sign Up

Patent: 2006
Patent: COMPUESTOS TRICÍCLICOS SUSTITUIDOS COMO INHIBIDORES DE RECEPTORES DEL FACTOR DE CRECIMIENTO DEL FIBROBLASTO (FGFR)
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 13287176
Patent: Substituted tricyclic compounds as FGFR inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 19200066
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Patent: 20270520
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Patent: 22291504
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2014030812
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 76689
Patent: COMPOSES TRICYCLIQUES SUBSTITUES UTILISES COMME INHIBITEURS DE FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 49881
Patent: COMPOSES TRICYCLIQUES SUBSTITUES UTILISES COMME INHIBITEURS DE FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 14003355
Patent: Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.
Estimated Expiration: ⤷  Sign Up

Patent: 17001984
Patent: Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014)
Estimated Expiration: ⤷  Sign Up

China

Patent: 4507943
Patent: Substituted tricyclic compounds as FGFR inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 7383009
Patent: 作为FGFR抑制剂的取代的三环化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 7652289
Patent: 作为FGFR抑制剂的取代的三环化合物 (Substituted tricyclic compounds as FGFR inhibitors)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 40375
Patent: Compuestos tricíclicos sustituidos como inhibidores del fgfr
Estimated Expiration: ⤷  Sign Up

Costa Rica

Patent: 140577
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR)
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0170430
Estimated Expiration: ⤷  Sign Up

Patent: 0190007
Estimated Expiration: ⤷  Sign Up

Patent: 0201966
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 18744
Estimated Expiration: ⤷  Sign Up

Patent: 21299
Estimated Expiration: ⤷  Sign Up

Patent: 23631
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 61595
Estimated Expiration: ⤷  Sign Up

Patent: 76170
Estimated Expiration: ⤷  Sign Up

Patent: 95367
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 15001225
Patent: COMPUESTOS TRICÍCLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS
Estimated Expiration: ⤷  Sign Up

Patent: 22091792
Patent: COMPUESTOS TRICÍCLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROPLASTOS
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 6592
Patent: ЗАМЕЩЕННЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 1590005
Patent: ЗАМЕЩЕННЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ FGFR
Estimated Expiration: ⤷  Sign Up

Patent: 2091923
Patent: ЗАМЕЩЕННЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ FGFR
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 61595
Patent: COMPOSÉS TRICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 76170
Patent: COMPOSÉS TRICYCLIQUES SUBSTITUÉS SERVANT D'INHIBITEURS DES FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 95367
Patent: COMPOSÉS TRICYCLIQUES SUBSTITUÉS SERVANT D'INHIBITEURS DES FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 22273
Patent: COMPOSÉS TRICYCLIQUES SUBSTITUÉS SERVANT D'INHIBITEURS DES FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 12326
Patent: 作為 抑制劑的取代的三環化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS FGFR)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 31916
Estimated Expiration: ⤷  Sign Up

Patent: 42374
Estimated Expiration: ⤷  Sign Up

Patent: 52195
Estimated Expiration: ⤷  Sign Up

Patent: 100035
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 6078
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷  Sign Up

Patent: 6976
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷  Sign Up

Patent: 6433
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷  Sign Up

Patent: 2622
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷  Sign Up

Patent: 9834
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 01321
Estimated Expiration: ⤷  Sign Up

Patent: 36665
Estimated Expiration: ⤷  Sign Up

Patent: 45863
Estimated Expiration: ⤷  Sign Up

Patent: 11946
Estimated Expiration: ⤷  Sign Up

Patent: 00170
Estimated Expiration: ⤷  Sign Up

Patent: 92096
Estimated Expiration: ⤷  Sign Up

Patent: 15521600
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物
Estimated Expiration: ⤷  Sign Up

Patent: 17222709
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 18135377
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 19178156
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 20143142
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 23027344
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 861595
Estimated Expiration: ⤷  Sign Up

Patent: 2021519
Estimated Expiration: ⤷  Sign Up

Patent: 61595
Estimated Expiration: ⤷  Sign Up

Patent: 76170
Estimated Expiration: ⤷  Sign Up

Patent: 95367
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 1375
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Patent: 8363
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 9293
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR). (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS.)
Estimated Expiration: ⤷  Sign Up

Patent: 14015192
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR). (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS.)
Estimated Expiration: ⤷  Sign Up

Patent: 22000517
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR). (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS.)
Estimated Expiration: ⤷  Sign Up

Montenegro

Patent: 651
Patent: SUBSTITUISANA TRICIKLIČNA JEDINJENJA KAO INHIBITORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 300
Patent: SUPSТITUISANA TRICIKLIČNA JEDINJENJA КАО INHIBIТORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Netherlands

Patent: 1131
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 2747
Patent: Substituted tricyclic compounds as fgfr inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 0134
Patent: Substituted tricyclic compounds as fgfr inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 3274
Patent: Substituted tricyclic compounds as fgfr inhibitors
Estimated Expiration: ⤷  Sign Up

Norway

Patent: 21034
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 150684
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR)
Estimated Expiration: ⤷  Sign Up

Patent: 190736
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR)
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 014502772
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Patent: 016502133
Patent: SUBSTITUTED TRICYCLE COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Patent: 019502809
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 61595
Estimated Expiration: ⤷  Sign Up

Patent: 76170
Estimated Expiration: ⤷  Sign Up

Patent: 95367
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 61595
Estimated Expiration: ⤷  Sign Up

Patent: 76170
Estimated Expiration: ⤷  Sign Up

Patent: 95367
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 908
Patent: SUBSTITUISANA TRICIKLIČNA JEDINJENJA KAO INHIBITORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 514
Patent: SUPSTITUISANA TRICIKLIČNA JEDINJENJA KAO INHIBITORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 089
Patent: SUPSTITUISANA TRICIKLIČNA JEDINJENJA KAO INHIBITORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201610416T
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Patent: 201408238W
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 61595
Estimated Expiration: ⤷  Sign Up

Patent: 76170
Estimated Expiration: ⤷  Sign Up

Patent: 95367
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2140426
Estimated Expiration: ⤷  Sign Up

Patent: 2406771
Estimated Expiration: ⤷  Sign Up

Patent: 2556118
Estimated Expiration: ⤷  Sign Up

Patent: 150036044
Patent: FGFR 억제제로서 치환된 트리사이클릭 화합물 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 200093696
Patent: FGFR 억제제로서 치환된 트리사이클릭 화합물 (FGFR SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 220080213
Patent: FGFR 억제제로서 치환된 트리사이클릭 화합물 (FGFR SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 18003
Estimated Expiration: ⤷  Sign Up

Patent: 04744
Estimated Expiration: ⤷  Sign Up

Patent: 32497
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 06953
Estimated Expiration: ⤷  Sign Up

Patent: 69529
Estimated Expiration: ⤷  Sign Up

Patent: 01156
Estimated Expiration: ⤷  Sign Up

Patent: 1402574
Patent: Substituted tricyclic compounds as FGFR inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 2124382
Patent: Substituted tricyclic compounds as fibroblast growth factor receptor inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 2241898
Patent: Substituted tricyclic compounds as fibroblast growth factor receptor inhibitors
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 7347
Patent: ЗАМІЩЕНІ ТРИЦИКЛІЧНІ СПОЛУКИ ЯК ІНГІБІТОРИ FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 5503
Patent: ЗАМІЩЕНІ ТРИЦИКЛІЧНІ СПОЛУКИ ЯК ІНГІБІТОРИ FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PEMAZYRE around the world.

Country Patent Number Title Estimated Expiration
Philippines 12020551850 SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME ⤷  Sign Up
Ecuador SP22091792 COMPUESTOS TRICÍCLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROPLASTOS ⤷  Sign Up
Australia 2022291504 SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS ⤷  Sign Up
Singapore 11202010636V SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME ⤷  Sign Up
Singapore 10201610416T SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS ⤷  Sign Up
Brazil 112020022392 formas sólidas de um inibidor de fgfr e processos para preparação das mesmas ⤷  Sign Up
Japan 2021523121 ＦＧＦＲ阻害剤の固体形態及びその調製プロセス ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Subscribe to access the full database, or Sign Up

Supplementary Protection Certificates for PEMAZYRE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2861595 122021000054 Germany ⤷  Sign Up PRODUCT NAME: PEMIGATINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1535 20210326
2861595 2190036-0 Sweden ⤷  Sign Up PRODUCT NAME: PEMIGATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1535 20210329
2861595 132021000000140 Italy ⤷  Sign Up PRODUCT NAME: PEMIGATINIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(PEMAZYRE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1535, 20210329
2861595 21C1041 France ⤷  Sign Up PRODUCT NAME: PEMIGATINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1535 20210329
2861595 2021C/536 Belgium ⤷  Sign Up PRODUCT NAME: PEMIGATINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1535 20210329
2861595 PA2021519 Lithuania ⤷  Sign Up PRODUCT NAME: PEMIGATINIBAS ARBA JO FARMACISKAI PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/21/1535 20210326
2861595 LUC00222 Luxembourg ⤷  Sign Up PRODUCT NAME: PEMIGATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/21/1535 20210329
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or Sign Up

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group